amorchem header logo close button Menu
arrow leftBack to portfolio

GAG

The main focus of this program is to optimize small molecule hits identified by Bellus Health for their activity in preventing immunoglobulin light chain aggregation, the main cause of AL amyloidosis. This program is a collaboration between Bellus Health, Dr. Bourgault (Université du Québec à Montréal) and NuChem Therapeutics.